Cibus (CBUS) AI Stock Analysis

• Market Cap: $171.61M
• Dividend Yield: N/A
• Average Volume (3M): 154.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.00
• Revenue Growth: -8.64%
• EPS Growth: 85.68%
• Country: US
• Employees: 157
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.59
• Shares Outstanding: 69,196,120
• 10 Day Avg. Volume: 164,630
• 30 Day Avg. Volume: 154,044
• PEG Ratio: 0.08
• Price to Book (P/B): 36.47
• Price to Sales (P/S): 218.79
• P/FCF Ratio: -15.56
• Enterprise Value/Market Cap: 2.27
• Enterprise Value/Revenue: 107.17
• Enterprise Value/Gross Profit: 448.27
• Enterprise Value/Ebitda: -6.34
• 1Y Price Target: $16.00
• Price Target Upside: 334.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.24
• Revenue Forecast (FY): $8.06M

• Rating: 52 Neutral
• Price Target: $3.00 ▼(-18.48% Downside)
• Action: Reiterated Date: 03/19/26
• Date: Action: Reiterated 03/19/26

The score is held back primarily by weak financial performance (ongoing losses, cash burn, and reduced equity base), which raises financing and dilution risk. This is partly offset by constructive earnings-call takeaways on regulatory/commercial milestones and cost actions extending runway, while technicals are mixed (longer-term trend intact but near-term weakness) and valuation provides limited support due to negative earnings and no dividend.

Positive Factors

Regulatory progress across major jurisdictions

Sustained regulatory clarity across the EU, UK, US and key Latin American markets materially lowers market-access barriers for gene-edited traits. Over 2–6 months this improves the probability of licensing, accelerates partner commercialization timelines and makes multi-region rollouts more feasible and durable.

Material platform efficiency improvements

An approximately 10x improvement in editing efficiency and a shorter 12–15 month edit cycle reduces R&D time and cost per trait, increasing throughput and competitiveness. This durable technical advance strengthens bargaining power with seed partners and supports faster commercialization and recurring licensing revenue over time.

Large rice partnership and royalty opportunity

A defined pipeline of partner customers and a multi-hundred-million-dollar potential royalty pool provide a clear, scalable commercialization path. Durable partner-led royalty model leverages existing seed channels, reduces capital intensity for Cibus, and can convert technology and regulatory gains into recurring cash flows if deployment milestones are met.

Negative Factors

Consistent negative free cash flow

Sustained negative operating and free cash flow forces reliance on external funding and constrains reinvestment choices. Over the medium term, persistent cash burn increases financing frequency and dilutive risk, and limits the company's ability to scale commercial activities without secured partner funding or new capital.

Sharply eroded equity base

A dramatic fall in equity over two years weakens balance-sheet resilience, narrows borrowing capacity, and makes future equity raises more dilutive. This structural deterioration increases the cost of capital and raises execution risk for multi-year commercialization investments absent material revenue conversion.

Very small, volatile revenue base and large losses

A minimal and inconsistent revenue profile coupled with large recurring losses means the business depends on successful, timely conversion of partnerships and regulatory wins into royalties. Until revenues scale predictably, margin sustainability and self-funded growth remain uncertain, sustaining financing and execution risk.

Cibus Business Overview & Revenue Model

Company Description

Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.

How the Company Makes Money

null

Cibus Financial Statement Overview

Summary

Financials reflect an early-stage biotech with very small/volatile revenue, persistent large net losses (2025 net loss ~$127.1M), and continued cash burn (2025 FCF about -$51.2M). Balance-sheet leverage is not extreme (~$33.0M debt), but equity has eroded sharply (to ~$21.8M in 2025), increasing dilution/financing risk.

Income Statement

Revenue is very small and volatile (roughly $0.2M–$25.9M historically, down to $3.6M in 2025), and the business remains deeply unprofitable with large operating losses and net losses each year (2025 net loss of about $127.1M). While gross profit improved versus earlier years (and was strong in 2023–2024), the overall earnings profile is weak due to heavy expense levels relative to revenue and a deterioration in revenue growth in 2025.

Balance Sheet

Leverage is moderate in absolute dollars (total debt ~$33.0M in 2025), but the equity base has fallen sharply over time (stockholders’ equity down from ~$293.5M in 2023 to ~$21.8M in 2025), which meaningfully reduces financial flexibility. With assets still sizable (~$305.0M in 2025), the main balance-sheet concern is the rapid erosion of equity from ongoing losses, increasing the risk of future dilution or tighter funding options.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow remaining meaningfully below zero every year (2025 operating cash flow about -$50.6M and free cash flow about -$51.2M). Free cash flow also deteriorated again in 2025 versus 2024, indicating continued cash burn and ongoing reliance on external financing to fund operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.64M	4.26M	1.82M	157.00K	25.99M
Gross Profit	-2.28M	4.26M	1.42M	-1.38M	-2.57M
EBITDA	-61.54M	-241.63M	-314.58M	-15.21M	-25.43M
Net Income	-127.08M	-251.39M	-267.63M	-16.89M	-29.20M
Balance Sheet
Total Assets	305.05M	350.07M	544.41M	22.42M	37.19M
Cash, Cash Equivalents and Short-Term Investments	9.92M	14.43M	32.70M	3.43M	13.82M
Total Debt	267.96M	36.29M	24.62M	13.91M	17.88M
Total Liabilities	283.22M	252.24M	206.12M	15.19M	23.06M
Stockholders Equity	21.83M	92.16M	293.47M	7.23M	14.13M
Cash Flow
Free Cash Flow	-51.17M	-58.85M	-50.53M	-20.88M	-19.31M
Operating Cash Flow	-50.59M	-58.04M	-46.21M	-19.36M	-18.81M
Investing Cash Flow	-578.00K	-808.00K	55.06M	-1.52M	11.20M
Financing Cash Flow	46.65M	40.60M	20.32M	9.99M	3.74M

Cibus Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.68
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Neutral. The current price of 3.68 is above the 20-day moving average (MA) of 3.47, above the 50-day MA of 2.65, and above the 200-day MA of 1.79, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 38.45 is Neutral, neither overbought nor oversold. The STOCH value of 1.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CBUS.

Cibus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CBUS	52 Neutral	$171.61M	-6.26	-236.85%	―	-8.64%	85.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XFOR	48 Neutral	$389.14M	-2.14	-115.27%	―	2925.73%	-294.29%
CRVO	47 Neutral	$37.22M	-2.65	-76.78%	―	-38.81%	-76.96%
OKYO	42 Neutral	$80.65M	-7.23	―	―	―	―
ABVC	41 Neutral	$31.04M	-6.26	-88.89%	―	56.52%	75.22%

Cibus Corporate Events

Cibus Announces Underwritten Public Offering of Common Stock

On January 29, 2026, Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for an underwritten public offering of 13,333,333 shares of its Class A common stock at $1.50 per share, with company board members participating for 1,000,000 shares at the offering price and a 30-day option granted to the underwriter to purchase up to an additional 1,999,999 shares. The deal, expected to close on or about January 30, 2026 subject to customary conditions, is projected to raise approximately $17.8 million in net proceeds, or $20.5 million if the overallotment option is fully exercised, and includes standard indemnification, a 60-day lock-up agreement for the company and its leadership, and a 6.25% underwriting discount plus reimbursement of the underwriter’s documented expenses, underscoring Cibus’s continued reliance on equity markets to secure funding while temporarily restricting insider share sales.

The most recent analyst rating on (CBUS) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus streamlines operations to focus on rice traits

In 2025, Cibus undertook a significant operational streamlining to concentrate capital and resources on commercializing its weed management traits for rice, including a workforce reduction of about 34 employees approved in July 2025 and completed by year-end, consolidation of core operations in San Diego, and deferral of non-partner-funded non-rice activities. Management estimates its rice herbicide tolerance traits could ultimately generate more than $200 million in annual royalties across initial target markets in Latin America and the United States, while its sustainable ingredients initiatives—particularly a yeast fermentation biofragrance program that began generating nominal payments in 2025—could reach $20–40 million in annual revenue over the long term; combined with cost-cutting measures expected to lower annual net cash usage to about $30 million or less in 2026, these moves aim to bolster financial stability while preserving upside from a broader trait portfolio that Cibus plans to advance opportunistically through partner-funded projects.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus executes minor internal Class A share repurchase

On December 31, 2025, Cibus, Inc. repurchased 60,088 shares of its Class A common stock from employee Anthony Moran at a nominal price of $0.0001 per share, under a share purchase agreement approved by the board of directors. The transaction represents a small, board-sanctioned internal equity reallocation involving an employee shareholder, with limited apparent impact on the company’s broader capital structure or external stakeholders.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.